Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common stock, par value $0.001 per share
-
Shares outstanding
-
9,388,240
-
Total 13F shares
-
2,603,802
-
Share change
-
+679,986
-
Total reported value
-
$101,367,311
-
Put/Call ratio
-
6.4%
-
Price per share
-
$38.97
-
Number of holders
-
63
-
Value change
-
+$26,943,937
-
Number of buys
-
42
-
Number of sells
-
13
Institutional Holders of Tvardi Therapeutics, Inc. - Common stock, par value $0.001 per share (TVRD) as of Q3 2025
As of 30 Sep 2025,
Tvardi Therapeutics, Inc. - Common stock, par value $0.001 per share (TVRD) was held by
63 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,603,802 shares.
The largest 10 holders included
Slate Path Capital LP, VANGUARD GROUP INC, BlackRock, Inc., 683 Capital Management, LLC, Vestal Point Capital, LP, GEODE CAPITAL MANAGEMENT, LLC, Invesco Ltd., FMR LLC, Parkman Healthcare Partners LLC, and STATE STREET CORP.
This page lists
63
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.